137 related articles for article (PubMed ID: 33752475)
41. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
42. Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.
Szopa M; Osmenda G; Wilk G; Matejko B; Skupien J; Zapala B; Młynarski W; Guzik T; Malecki MT
Eur J Endocrinol; 2015 Mar; 172(3):277-83. PubMed ID: 25501962
[TBL] [Abstract][Full Text] [Related]
43. Defective functions of HNF1A variants on BCL2L1 transactivation and beta-cell growth.
Sujjitjoon J; Charoensuk C; Thanyaphon T; Kooptiwut S; Thamtarana PJ; Tangjittipokin W; Chongjaroen N; Chanprasert C; Abubakar Z; Lapbenjakul S; Yenchitsomanus PT; Plengvidhya N
Biochem Biophys Res Commun; 2020 Aug; 529(3):826-833. PubMed ID: 32684311
[TBL] [Abstract][Full Text] [Related]
44. The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1.
Ding CH; Yin C; Chen SJ; Wen LZ; Ding K; Lei SJ; Liu JP; Wang J; Chen KX; Jiang HL; Zhang X; Luo C; Xie WF
Mol Cancer; 2018 Feb; 17(1):63. PubMed ID: 29466992
[TBL] [Abstract][Full Text] [Related]
45. HNF1α controls glucagon secretion in pancreatic α-cells through modulation of SGLT1.
Sato Y; Rahman MM; Haneda M; Tsuyama T; Mizumoto T; Yoshizawa T; Kitamura T; Gonzalez FJ; Yamamura KI; Yamagata K
Biochim Biophys Acta Mol Basis Dis; 2020 Nov; 1866(11):165898. PubMed ID: 32711050
[TBL] [Abstract][Full Text] [Related]
46. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young.
Ellard S; Thomas K; Edghill EL; Owens M; Ambye L; Cropper J; Little J; Strachan M; Stride A; Ersoy B; Eiberg H; Pedersen O; Shepherd MH; Hansen T; Harries LW; Hattersley AT
Diabetologia; 2007 Nov; 50(11):2313-7. PubMed ID: 17828387
[TBL] [Abstract][Full Text] [Related]
47. Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage.
Jeannot E; Mellottee L; Bioulac-Sage P; Balabaud C; Scoazec JY; Tran Van Nhieu J; Bacq Y; Michalak S; Buob D; ; Laurent-Puig P; Rusyn I; Zucman-Rossi J
Diabetes; 2010 Jul; 59(7):1836-44. PubMed ID: 20393147
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study).
Eide SA; Raeder H; Johansson S; Midthjell K; Søvik O; Njølstad PR; Molven A
Diabet Med; 2008 Jul; 25(7):775-81. PubMed ID: 18513305
[TBL] [Abstract][Full Text] [Related]
49. Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model.
Urbanova J; Andel M; Potockova J; Klima J; Macek J; Ptacek P; Mat'oska V; Kumstyrova T; Heneberg P
Curr Pharm Des; 2015; 21(39):5736-48. PubMed ID: 26446475
[TBL] [Abstract][Full Text] [Related]
50. Assessing the association of the HNF1A G319S variant with C-reactive protein in Aboriginal Canadians: a population-based epidemiological study.
Ley SH; Hegele RA; Connelly PW; Harris SB; Mamakeesick M; Cao H; Gittelsohn J; Retnakaran R; Zinman B; Hanley AJ
Cardiovasc Diabetol; 2010 Aug; 9():39. PubMed ID: 20716378
[TBL] [Abstract][Full Text] [Related]
51. Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A.
Hoskins JW; Jia J; Flandez M; Parikh H; Xiao W; Collins I; Emmanuel MA; Ibrahim A; Powell J; Zhang L; Malats N; Bamlet WR; Petersen GM; Real FX; Amundadottir LT
Carcinogenesis; 2014 Dec; 35(12):2670-8. PubMed ID: 25233928
[TBL] [Abstract][Full Text] [Related]
52. Clinical heterogeneity of hyperinsulinism due to HNF1A and HNF4A mutations.
Tung JY; Boodhansingh K; Stanley CA; De León DD
Pediatr Diabetes; 2018 Aug; 19(5):910-916. PubMed ID: 29493090
[TBL] [Abstract][Full Text] [Related]
53. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
[TBL] [Abstract][Full Text] [Related]
54. Rapamycin protects against dominant negative-HNF1A-induced apoptosis in INS-1 cells.
Farrelly AM; Kilbride SM; Bonner C; Prehn JH; Byrne MM
Apoptosis; 2011 Nov; 16(11):1128-37. PubMed ID: 21874357
[TBL] [Abstract][Full Text] [Related]
55. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
[TBL] [Abstract][Full Text] [Related]
56. The lncRNA HNF1A-AS1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma.
Cai L; Lv J; Zhang Y; Li J; Wang Y; Yang H
J Cell Mol Med; 2017 Nov; 21(11):2654-2662. PubMed ID: 28866868
[TBL] [Abstract][Full Text] [Related]
57. The HNF1A-AS1/miR-92a-3p axis affects the radiosensitivity of non-small cell lung cancer by competitively regulating the JNK pathway.
Wang Z; Liu L; Du Y; Mi Y; Wang L
Cell Biol Toxicol; 2021 Oct; 37(5):715-729. PubMed ID: 33755848
[TBL] [Abstract][Full Text] [Related]
58. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
[TBL] [Abstract][Full Text] [Related]
59. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer.
Chen F; Fan Y; Hou J; Liu B; Zhang B; Shang Y; Chang Y; Cao P; Tan K
Aging (Albany NY); 2021 Sep; 13(17):21671-21699. PubMed ID: 34518441
[TBL] [Abstract][Full Text] [Related]
60. Hepatocyte nuclear factor 1 alpha (HNF1A) regulates transcription of O-GlcNAc transferase in a negative feedback mechanism.
Zhang C; Xie F; Li L; Zhang C; Zhang Y; Ying W; Liu L; Yan X; Yin F; Zhang L
FEBS Lett; 2019 May; 593(10):1050-1060. PubMed ID: 30953348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
